Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol
Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control
Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study
Key Exclusion Criteria:
History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol
History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock
History of eosinophilic Gastrointestinal (GI) disease
Asthma at time of enrollment with any of the following:
Forced Expiratory Volume 1 Second (FEV1) <80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) <75% of predicted with or without controller medications
Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)
One hospitalization in the past year for asthma
Emergency room visit for asthma within 6 months prior to screening
Use of systemic corticosteroids within 2 months prior to screening
Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening
Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening
Allergy to oat (placebo in DBPCFC)
Note: Other protocol Inclusion/Exclusion Criteria apply
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
dupilumab + AR101
Donnée non disponible
Participant randomization of a ratio of 2 active dupilumab arms
Inconnu
placebo matching dupilumab + AR101
Donnée non disponible
Participant randomization of a ratio of 1 placebo arm
Inconnu
dupilumab + AR101
État du recrutement
unknown
Participant randomization of a ratio of 2 active dupilumab arms
placebo matching dupilumab + AR101
État du recrutement
unknown
Participant randomization of a ratio of 1 placebo arm
Données à jour depuis :
11 février 2024
Description de l'étude
Description de l'étude
Résumé de l'étude
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.
Secondary objectives are:
To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16
To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo
To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio
To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary [e-diary]) during the up-dosing phase
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
10
affichés
sur
24
centres
REGENERON INVESTIGATIONAL SITE
Philadelphia
PENNSYLVANIA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Chapel hill
NORTH CAROLINA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
New york
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Great neck
NEW YORK, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Ocean township
NEW JERSEY, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Minneapolis
MINNESOTA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Ypsilanti
MICHIGAN, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Ann arbor
MICHIGAN, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Boston
MASSACHUSETTS, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
REGENERON INVESTIGATIONAL SITE
Seattle
WASHINGTON, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
Centres participants
Source d'information
Dernière modification :
11 février 2024
Données à jour depuis :
11 fév.
Origine des données :
clinicaltrials.gov